These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1281 related articles for article (PubMed ID: 24502656)

  • 1. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
    Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
    J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
    Guo Z; Wang H; Meng F; Li J; Zhang S
    J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer.
    Guo Z; Wang X; Cheng D; Xia Z; Luan M; Zhang S
    PLoS One; 2014; 9(2):e89350. PubMed ID: 24586709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carboplatin and programmed death-ligand 1 blockade synergistically produce a similar antitumor effect to carboplatin alone in murine ID8 ovarian cancer model.
    Zhu X; Xu J; Cai H; Lang J
    J Obstet Gynaecol Res; 2018 Feb; 44(2):303-311. PubMed ID: 29171115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer.
    Guo Z; Cheng D; Xia Z; Luan M; Wu L; Wang G; Zhang S
    J Transl Med; 2013 Sep; 11():215. PubMed ID: 24044888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
    Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
    Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peritumoral administration of DRibbles-pulsed antigen-presenting cells enhances the antitumor efficacy of anti-GITR and anti-PD-1 antibodies via an antigen presenting independent mechanism.
    Patel JM; Cui Z; Wen ZF; Dinh CT; Hu HM
    J Immunother Cancer; 2019 Nov; 7(1):311. PubMed ID: 31747946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.
    Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H
    Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-α gene therapy for pancreatic cancer.
    Aida K; Miyakawa R; Suzuki K; Narumi K; Udagawa T; Yamamoto Y; Chikaraishi T; Yoshida T; Aoki K
    Cancer Sci; 2014 Feb; 105(2):159-67. PubMed ID: 24289533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer.
    Zhu X; Lang J
    J Gynecol Oncol; 2017 Sep; 28(5):e64. PubMed ID: 28657225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin.
    Wei H; Zhao L; Li W; Fan K; Qian W; Hou S; Wang H; Dai M; Hellstrom I; Hellstrom KE; Guo Y
    PLoS One; 2013; 8(12):e84927. PubMed ID: 24367702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy.
    Shrimali R; Ahmad S; Berrong Z; Okoev G; Matevosyan A; Razavi GSE; Petit R; Gupta S; Mkrtichyan M; Khleif SN
    J Immunother Cancer; 2017 Aug; 5(1):64. PubMed ID: 28807056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pivotal roles of CD4+ effector T cells in mediating agonistic anti-GITR mAb-induced-immune activation and tumor immunity in CT26 tumors.
    Zhou P; L'italien L; Hodges D; Schebye XM
    J Immunol; 2007 Dec; 179(11):7365-75. PubMed ID: 18025180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-glucocorticoid-induced Tumor Necrosis Factor-Related Protein (GITR) Therapy Overcomes Radiation-Induced Treg Immunosuppression and Drives Abscopal Effects.
    Schoenhals JE; Cushman TR; Barsoumian HB; Li A; Cadena AP; Niknam S; Younes AI; Caetano MDS; Cortez MA; Welsh JW
    Front Immunol; 2018; 9():2170. PubMed ID: 30294332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer.
    Duraiswamy J; Freeman GJ; Coukos G
    Cancer Res; 2013 Dec; 73(23):6900-12. PubMed ID: 23975756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic antitumor responses by combined GITR activation and sunitinib in metastatic renal cell carcinoma.
    Yu N; Fu S; Xu Z; Liu Y; Hao J; Zhang A; Wang B
    Int J Cancer; 2016 Jan; 138(2):451-62. PubMed ID: 26239999
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Wang B; Zhang W; Jankovic V; Golubov J; Poon P; Oswald EM; Gurer C; Wei J; Ramos I; Wu Q; Waite J; Ni M; Adler C; Wei Y; Macdonald L; Rowlands T; Brydges S; Siao J; Poueymirou W; MacDonald D; Yancopoulos GD; Sleeman MA; Murphy AJ; Skokos D
    Sci Immunol; 2018 Nov; 3(29):. PubMed ID: 30389797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GITR Agonism Enhances Cellular Metabolism to Support CD8
    Sabharwal SS; Rosen DB; Grein J; Tedesco D; Joyce-Shaikh B; Ueda R; Semana M; Bauer M; Bang K; Stevenson C; Cua DJ; Zúñiga LA
    Cancer Immunol Res; 2018 Oct; 6(10):1199-1211. PubMed ID: 30154083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of tumor immunity: a patent evaluation of WO2015026684A1.
    Nocentini G; Cari L; Ronchetti S; Riccardi C
    Expert Opin Ther Pat; 2016; 26(3):417-25. PubMed ID: 26560753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity.
    Cohen AD; Diab A; Perales MA; Wolchok JD; Rizzuto G; Merghoub T; Huggins D; Liu C; Turk MJ; Restifo NP; Sakaguchi S; Houghton AN
    Cancer Res; 2006 May; 66(9):4904-12. PubMed ID: 16651447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 65.